The prognosis for patients multiple myeloma (MM) has improved substantially over the past
decade with the development of new, more effective chemotherapeutic agents and regimens …

1Bristol Haematology and Oncology Centre, University Hospitals Bristol NHS Foundation
Trust, Bristol, 2Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds …

Defining conditioning regimen intensity has become a critical issue for the hemopoietic stem
cell transplant (HSCT) community. In the present report we propose to define conditioning …

We previously reported that the Charlson Comorbidity Index (CCI) was useful for predicting
outcomes in patients undergoing allogeneic hematopoietic cell transplantation (HCT) …

Multiple myeloma (MM) is caused by the neoplastic proliferation of plasma cells. These
neoplastic plasma cells proliferate and produce monoclonal immunoglobulin in the bone …

The treatment of multiple myeloma has changed dramatically in the past decade. The
increase in the number of active agents has generated numerous possible drug …

The ability of allogeneic bone-marrow cells and peripheral-blood stem cells to cure
leukaemia remains the most striking example of the ability of the human immune system to …

Context A minimally toxic nonmyeloablative regimen was developed for allogeneic
hematopoietic cell transplantation (HCT) to treat patients with advanced hematologic …

Purpose Results of a prospective randomized trial conducted by the Intergroupe Francais du
Myélome (IFM 90) indicated that autologous hematopoietic cell–supported high-dose …

Background In this trial of the treatment of newly diagnosed multiple myeloma, we compared
a protocol that entailed a hematopoietic stem-cell autograft followed by an allograft from an …